Population Stratification Sample Clauses

Population Stratification. Re-id for direct care purposes only
AutoNDA by SimpleDocs
Population Stratification. Re-id in controlled environment for direct care purposes only
Population Stratification. Use Case 4: Place Based COVID related analysis as outlined in the COPI Notice
Population Stratification. Use Case 4: Place Based COVID related analysis as outlined in the COPI Notice 10 Additional GP Information • GP Encounter • Vaccinations & Immunisations • Contraindications • OTC and Prophylactic Therapy • Family History Use Case 1: Demand and Capacity Use Case 3: Population Stratification. • Child Health • Diabetes Diagnosis • Chronic Disease Monitoring • Medication Administration • Pregnancy, Birth and Post Natal • Contraception and HRT • GP Imaging • Other Investigations • Investigations Administration • Operations • Obstetric Procedures • Other Diagnostic Procedures • ECG • Other Preventative Procedures • Other Therapeutic Procedures • Recent Test Results (last 12 months) Use Case 4: Place Based COVID related analysis as outlined in the COPI Notice 12 Data Categories • Active Problems • Administration • Alcohol Exercise and Diet • Allergy • Blood Chemistry • Blood Pressure • Cervical Cytology • Child Health • Chronic Disease Monitoring • Contraception and HRT • Contraindications • Diabetes Diagnosis • ECG Pulmonary • Encounters • Family History • Full Problems List • Glucose/hba1c • Haematology • Height and Weight • Imaging • Investigations Admin • Medications Administration • Medication Issues • Microbiology • Obstetric Procedures • Operations • OTC Prophylactic Therapy • Other Cytology/Pathology • Other Diagnostic Procedures • Other Investigations • Other Preventative Procedures • Other Therapeutic Procedures • Past Problems • Physiology Function Tests • Pregnancy, Birth and Post Natal • Recent Tests Use Case 1: Demand and Capacity Use Case 2: Epidemiology Use Case 3: Population Stratification. Use Case 4: Place Based COVID related analysis as outlined in the COPI Notice • Referrals and Admissions • Repeat Medication • Smoking • Social History • Unmatched • Urinalysis • Vaccination and Immunisations
Population Stratification. Use Case 4: Place Based COVID related analysis as outlined in the COPI Notice 4 Allergies Summary
Population Stratification. The population shall be stratified and reported by race and ethnicity in accordance with the associated measure specifications.
Population Stratification. Use Case 4: Place Based COVID related analysis as outlined in the COPI Notice 6 GP Problems • Active Problems • Past Problems • Additional Problems Use Case 2: Epidemiology Use Case 3: Population Stratification. Use Case 4: Place Based COVID related analysis as outlined in the COPI Notice
AutoNDA by SimpleDocs

Related to Population Stratification

  • Study Population Infants who underwent creation of an enterostomy receiving postoperative care and awaiting enterostomy closure: to be assessed for eligibility: n = 230 to be assigned to the study: n = 120 to be analysed: n = 120 Duration of intervention per patient of the intervention group: minimum 21 days/3 weeks until patient’s weight >2000g, averaged 6 weeks between enterostomy creation and enterostomy closure Follow-up per patient: 3 months, 6 months and 12 months following enterostomy closure (12- month follow-up only applicable for patients that are recruited early enough to complete this follow-up within the 48 months of overall study duration).

  • Target Population TREATMENT FOR ADULT (TRA) Target Population

  • Population The Population shall be defined as all Paid Claims during the 12-month period covered by the Claims Review.

  • Study An application for leave of absence for professional study must be supported by a written statement indicating what study or research is to be undertaken, or, if applicable, what subjects are to be studied and at what institutions.

  • Prescription Drug Plan Retail and mail order prescription drug copays for bargaining unit employees shall be as follows:

  • Registry Interoperability and Continuity Registry Operator shall comply with the Registry Interoperability and Continuity Specifications as set forth in Specification 6 attached hereto (“Specification 6”).

  • Human Leukocyte Antigen Testing This plan covers human leukocyte antigen testing for A, B, and DR antigens once per member per lifetime to establish a member’s bone marrow transplantation donor suitability in accordance with R.I. General Law §27-20-36. The testing must be performed in a facility that is: • accredited by the American Association of Blood Banks or its successors; and • licensed under the Clinical Laboratory Improvement Act as it may be amended from time to time. At the time of testing, the person being tested must complete and sign an informed consent form that also authorizes the results of the test to be used for participation in the National Marrow Donor program.

  • DRUG/ALCOHOL TESTING Section 33.1 Drug testing may be conducted on employees during their duty hours upon reasonable suspicion or randomly by computer selection. Alcohol testing will be conducted only upon reasonable suspicion. Reasonable suspicion that an employee used or is using a controlled substance or alcohol in an unlawful or abusive manner may be based upon, but not limited to: A. Observable phenomena, such as direct observation of drug or alcohol use or possession and/or the physical symptoms of being under the influence of a drug or alcohol; B. A pattern or abnormal conduct or erratic behavior, including abnormal leave patterns; C. Arrest or conviction for a drug or alcohol-related offense, or the identification of an employee as the focus of a criminal investigation into illegal drug or alcohol possession, use, or trafficking; D. Information provided either by reliable and credible sources or independently corroborated; E. Evidence that an employee has tampered with a previous drug test; F. Facts or circumstances developed in the course of an authorized investigation of an accident or unsafe working practices. Section 33.2 Drug/alcohol testing shall be conducted solely for administrative purposes and the results obtained shall not be used in criminal proceedings. Under no circumstances may the results of drug/alcohol screening or testing be released to a third party for use in a criminal prosecution against the affected employee. The following procedure shall not preclude the Employer from other administrative action but such actions shall not be based solely upon the initial reagent testing results alone. Section 33.3 All drug screening tests shall be conducted by laboratories meeting the standards of the Substance Abuse and Mental Health Service Administration. No test shall be considered positive until it has been confirmed by a Gas Chromatography/Mass Spectrometry. The procedures utilized by the Employer and testing laboratory shall include an evidentiary chain of custody control and split sample testing. All procedures shall be outlined in writing and this outline shall be followed in all situations arising under this article. Section 33.4 Alcohol testing shall be done in accordance with the law of the State of Ohio to detect drivers operating a motor vehicle under the influence. A positive result shall entitle the Employer to proceed with sanctions as set forth in this Article. Section 33.5 The results of the testing shall be delivered to a specified employee of the Employer with command responsibility and the employee tested. An employee whose confirmatory test result is positive shall have the right to request a certified copy of the testing results in which the vendor shall affirm that the test results were obtained using the approved protocol methods. The employee shall provide a signed release for disclosure of the testing results to the Employer. A representative for the bargaining unit shall have a right of access to the results upon request to the Employer, with the employee’s written consent. Refusal to submit to the testing provided for under this Agreement may be grounds for discipline. A. If a drug screening test is positive, a confirmatory test shall be conducted utilizing the fluid from the primary sample. B. In the event that any confirmation drug test results are positive, the employee is entitled to have the split sample tested by another DHHS-certified lab in the manner prescribed above at the employee’s expense. The employee must request the split sample test within seventy-two (72) hours of being notified of a positive result. The results of this test, whether positive or negative, shall be determinative. Section 33.7 A list of three (3) testing laboratories shall be maintained by the Employer. These laboratories shall conduct any testing directed by the Employer. The Employer shall obtain the approval of the bargaining unit representative as to any laboratories put on this list, which approval shall not be unreasonably withheld. Section 33.8 If after the testing required above has produced a positive result the Employer may require the employee to participate in any rehabilitation or detoxification program that is covered by the employee’s health insurance. Discipline allowed by the positive findings provided for above shall be deferred pending rehabilitation of the employee within a reasonable period. An employee who participates in a rehabilitation or detoxification program shall be allowed to use sick time and vacation leave for the period of the rehabilitation or detoxification program. If no such leave credits are available, the employee shall be placed on medical leave of absence without pay for the period of the rehabilitation or detoxification program. Upon completion of such program and upon receiving results from a retest demonstrating that the employee is no longer abusing a controlled substance/alcohol, the employee shall be returned to his/her former position. Such employee may be subject to periodic retesting upon his/her return to his/her position for a period of one (1) year from the date of his/her return to work. Any employee in a rehabilitation or detoxification program in accordance with this Article will not lose any seniority or benefits, should it be necessary for the employee to be placed on medical leave of absence without pay, for a period not to exceed ninety (90) days. Section 33.9 If the employee refuses to undergo rehabilitation or detoxification, or if he/she tests positive during a retesting within one (1) year after his/her return to work from such a program, the employee shall be subject to disciplinary action, including removal from his/her position and termination of his/her employment. Section 33.10 Costs of all drug screening tests and confirmatory tests shall be borne by the Employer except that any test initiated at the request of the employee shall be at the employee’s expense. Section 33.11 The Employer may conduct four (4) tests of an employee during the one (1) year period after the employee has completed a rehabilitation or detoxification program as provided above. Section 33.12 The provisions of this Article shall not require the Employer to offer a rehabilitation/detoxification program to any employee more than once.

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!